Genomic Valley Biotech Ltd (GVBL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Genomic Valley Biotech Ltd on NSE and BSE, with an AI summary of each filing.
Fintellectual Corporate Advisors Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Draft Letter of Offer for the attention of the Public Shareholders of Genomic Valley Biotech ....
Others (Uncategorized) · 03 Nov 2026, 11:45 pm
Pankaj Grover and Abhisek Gupta Launch Open Offer for Genomic Valley Biotech Pankaj Grover and Abhisek Gupta announced a mandatory open offer to acquire up to 7,94,170 equity shares, representing 26% of the voting share capital of Genomic Valley Biotech Ltd, at ₹30 per share in cash, aggregating to ₹2.38 cr. This follows an underlying share purchase agreement dated 19th Oct'26 to acquire 14,07,000 shares (46.06% stake) at ₹30 per share for ₹4.22 cr, triggering a management control change. The tendering period is scheduled from 14th Dec'26 to 28th Dec'26, with completion targeted by 11th Jan'27.
Please find enclosed herewith unaudited standalone financial results for the quarter and half yearly ended on September 30, 2026
Financial Result · 30 Oct 2026, 11:43 pm
Genomic Valley Biotech Reports Q2 FY27 Loss on Zero Revenue Genomic Valley Biotech reported zero revenue from operations for Q2 ended 30th Sep'26, down from ₹3.80 lakh in Q1 ended 30th Jun'26 and ₹9.00 lakh in Q2 ended 30th Sep'25. Total expenses stood at ₹1.98 lakh versus ₹2.34 lakh QoQ and ₹8.67 lakh YoY. Consequently, the company posted a net loss of ₹1.98 lakh compared to a net profit of ₹1.46 lakh QoQ and ₹0.33 lakh YoY, resulting in basic and diluted EPS of -₹0.06. H1 net loss stood at ₹0.52 lakh.
Please find enclosed herewith Outcome of Board Meeting Pursuant to regulation 30 of Sebi (LODR)Regulation, 2015 held on today i.e. 30th October 2026
Outcome · 30 Oct 2026, 11:29 pm
Genomic Valley Biotech Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR) ■ Revenue: 0.0 (-100.0% YoY | -100.0% QoQ) ■ EBITDA: -1,89,731 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): 0.0 (-4561 bps YoY | -4057 bps QoQ) ■ PAT: -1,97,731 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -0.06 (Profit to Loss YoY | Profit to Loss QoQ)
Fintellectual Corporate Advisors Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Detailed Public Statement in terms of Regulation 3(1) and Regulation 4 read with Regulation ....
Others (Uncategorized) · 27 Oct 2026, 8:44 pm
Open Offer for Genomic Valley Biotech Acquisition Pankaj Grover and Abhisek Gupta have launched an open offer to acquire up to 7,94,170 fully paid-up equity shares (representing 26.00% of voting share capital) of Genomic Valley Biotech Ltd at an offer price of ₹30.00 per share. The mandatory cash offer follows a Share Purchase Agreement dated 19th Oct'26 to acquire 14,07,000 equity shares (46.06% stake) from promoter Yogesh Agrawal for ₹4.22 crore (₹30.00 per share), triggering a change in control and management. Fintellectual Corporate Advisors is acting as manager to the offer.
Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve the unaudited financial ....
Intimation · 30 Oct 2026, 5:30 am
Genomic Valley Biotech Board Meeting on 30th Oct'26 for Q2 Earnings Genomic Valley Biotech Limited has scheduled its Board of Directors meeting on 30th Oct'26 to consider and approve standalone unaudited financial results for the quarter and half-year ended 30th Sep'26. In compliance with SEBI insider trading regulations, the trading window for dealing in company securities has been closed from 1st Oct'26 and will reopen 48 hours after the financial results are made public.
Disclosure under Regulation 30 and Regulation 30A of the SEBI (LODR) Regulations, 2015 regarding Mr. Yogesh Agrawal (hereinafter referred to as the "Promoters" or "Promoter Sellers") of ....
Others (Uncategorized) · 20 Oct 2026, 9:42 pm
Genomic Valley Biotech Announces Promoter Stake Sale and Open Offer Promoter Yogesh Agrawal executed a Share Purchase Agreement on 19th Oct'26 to sell his entire stake of 14,07,000 equity shares (46.06% of voting share capital) in Genomic Valley Biotech Limited to Pankaj Grover and Abhisek Gupta. The transaction will trigger a mandatory open offer under SEBI SAST Regulations. Following the completion of the open offer and transaction, the acquirers will gain management control and be reclassified as promoters, while existing promoter directors will resign from the board.
Fintellectual Corporate Advisors Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Public Announcement ("PA") under Regulation 3(1) and Regulation 4 read with Regulation ....
Others (Uncategorized) · 19 Oct 2026, 11:26 pm
Open Offer Announced for 26% Stake in Genomic Valley Biotech Pankaj Grover and Abhisek Gupta have announced an open offer to acquire up to 7,94,170 equity shares, representing 26.00% of the voting share capital of Genomic Valley Biotech Ltd, at ₹30 per share payable in cash, totaling ₹2.38 crore. The mandatory offer follows a share purchase agreement executed on 19th Oct'26 with promoter seller Yogesh Agrawal to acquire 14,07,000 equity shares (46.06% stake) at ₹30 per share for ₹4.22 crore, which will fully exit the seller's holdings in the company.
Intimation of approval of Extension of time for holding Annual General Meeting (AGM) of the company for the financial year ended on 31st March 2026, pursuant to regulation 30 of SEBI (Listing ....
Others (Uncategorized) · 31 Aug 2026, 9:03 pm
Unaudited financial results for Quarter ended on 30 June 2026.
Financial Result · 14 Aug 2026, 10:05 pm
Genomic Valley Biotech Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR) ■ Revenue: 3,80,000 (-57.8% YoY | +1.3% QoQ) ■ EBITDA: 1,54,162 (-39.4% YoY | +437.4% QoQ) ■ EBITDA Margin (%): 40.6 (+1229 bps YoY | +3292 bps QoQ) ■ PAT: 1,46,162 (-40.7% YoY | Loss to Profit QoQ) ■ EPS (INR): 0.05 (-37.5% YoY | Loss to Profit QoQ)
Considered and approved the standalone Un-audited financial results of the company for the quarter ended on 30th June 2026.
Outcome · 14 Aug 2026, 9:29 pm
Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve unaudited financial ....
Intimation · 14 Aug 2026, 5:30 am
Genomic Valley Biotech Board to Approve Q1FY27 Results on 14th Aug'26 Genomic Valley Biotech's Board of Directors will meet on 14th Aug'26 to consider and approve unaudited standalone financial results for the quarter ended 30th Jun'26. Consequently, the trading window for designated persons is closed from 01st Jul'26 and will reopen 48 hours after the results are publicly announced. The meeting date serves as a key catalyst for the stock, with market participants anticipating the Q1 financial performance.
Appointment of Mr. Navjyoti Kumar Jha as internal auditor of the company for the F.Y. 2026-27.
Change in Auditor · 30 May 2026, 12:14 am
Genomic Valley Board Approves FY26 Results and New Internal Auditor Genomic Valley Biotech's board approved audited financial results for the quarter and year ended 31 Mar'26. For FY26, the company reported revenue of Rs 26.75 lakh and a net profit of Rs 3.03 lakh, a sharp decline from Rs 84.84 lakh and Rs 35.61 lakh respectively in FY25. Q4 FY26 revenue was Rs 3.75 lakh with a net loss of Rs 0.82 lakh. The board also approved the appointment of Mr. Navjyoti Kumar Jha as Internal Auditor for FY 2026-27.
Standalone audited financial results of the company for the quarter and year ended on 31 March 2026.
Financial Result · 30 May 2026, 12:02 am
Genomic Valley Biotech Reports Q4FY26 Results and Appoints New Internal Auditor Genomic Valley Biotech’s Board approved Q4 and FY26 audited financial results on 29-May'26. For Q4FY26, the company posted a net loss of Rs 81,745 versus a loss of Rs 8.35 lakh YoY. Revenue from operations was Rs 3.75 lakh, down from Rs 26.35 lakh YoY. For the full year FY26, net profit was Rs 3.03 lakh, a sharp decline from Rs 35.61 lakh in FY25. Revenue for FY26 stood at Rs 26.75 lakh, down from Rs 84.39 lakh YoY. The board also appointed Navjyoti Kumar Jha as Internal Auditor.
1. Considered and approved the standalone audited financial results of the company for the quarter and financial year ended 31st March 2026; 2. Considered and approved the appointment ....
Outcome · 29 May 2026, 11:14 pm
Genomic Valley Biotech Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR) ■ Revenue: 3,75,000 (-85.8% YoY | -25.0% QoQ) ■ EBITDA: 28,688 (+1.4% YoY | -74.7% QoQ) ■ EBITDA Margin (%): 7.7 (+658 bps YoY | -1499 bps QoQ) ■ PAT: -81,745 (+90.2% YoY | Profit to Loss QoQ) ■ EPS (INR): -0.03 (+90.1% YoY | Profit to Loss QoQ)
Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the audited financial ....
Intimation · 29 May 2026, 5:30 am
Genomic Valley Biotech Board Meeting for Q4 and FY26 Results Genomic Valley Biotech (GVBL) has scheduled a Board of Directors meeting on 29th May'26 to consider and approve the audited standalone financial results for the quarter and year ended 31st Mar'26. In compliance with SEBI insider trading regulations, the company has closed its trading window for designated persons from 01st Apr'26. The window will remain closed until 48 hours after the financial results are publicly announced on 29th May'26.
Disclosure made by Promoters and Promoters group of the company under Regulation 31(4) of SEBI (substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the financial year ....
Others (Uncategorized) · 03 Apr 2026, 6:31 pm
Genomic Valley Biotech: Promoter Declares No Share Encumbrance in FY26 Genomic Valley Biotech (BSE: 539206) Promoter Yogesh Agrawal has declared that he, along with other promoters and persons acting in concert, has not created any direct or indirect encumbrance on their shares. This declaration, filed on 01 Apr'26, is under Regulation 31(4) of SEBI (SAST) Regulations, 2011 and covers the financial year ended 31 Mar'26. The filing confirms that promoter shareholding remains unpledged for the period. The promoter group includes Yogesh Agrawal, Parul Agrawal, and Ojaswini Avantika.
Disclosure made by Promoters and Promoters group of the company under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the financial year ....
Others (Uncategorized) · 01 Apr 2026, 9:58 pm
Genomic Valley Biotech Promoters Declare No Share Encumbrance for FY26 Genomic Valley Biotech (BSE: 539206) Promoter Yogesh Agrawal filed a declaration under SEBI Takeover Regulations on 01 Apr'26, confirming that no shares held by the promoter and promoter group were encumbered during the financial year ended 31 Mar'26. The filing lists Yogesh Agrawal and Parul Agrawal as promoters, and Ojaswini Avantika as part of the promoter group, all of whom are covered by this nil encumbrance declaration. This signals stability in promoter shareholding for the specified period.
Cessation of Mr. Ashok Kumar (DIN: 07647876) from the directorship of the company.
Change in Management · 15 Jan 2026, 11:38 pm
GVBL Q3FY26 Revenue and Profit Decline Sharply YoY; Director Resigns Genomic Valley Biotech (GVBL) reported Q3FY26 results for the quarter ended 31st Dec'25, with revenue at ₹5 lakh, a 97.7% YoY decline. Profit after tax (PAT) fell 93.2% YoY to ₹1.05 lakh. On a QoQ basis, revenue dropped 44.4% while PAT increased by 218%. The board also approved the cessation of Mr. Ashok Kumar as a director, effective 15th Jan'26, due to non-completion of KYC requirements pursuant to Section 167 of the Companies Act, 2013.
Please find enclosed herewith the financial results for the Quarter and Nine Months ended 31st December 2025, pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) ....
Financial Result · 15 Jan 2026, 11:33 pm
GENOMIC VALLEY BIOTECH LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR) ■ Revenue: 500000 (-77.3% YoY | -44.4% QoQ) ■ EBITDA: 113206 (-92.7% YoY | +175.8% QoQ) ■ EBITDA Margin (%): 22.6 (-4799 bps YoY | +1808 bps QoQ) ■ PAT: 105206 (-93.2% YoY | +218.3% QoQ) ■ EPS (INR): 0.03 (-94.1% YoY | +200.0% QoQ)
Please find enclosed herewith the Outcome of the Board Meeting dated 15/01/2026 for your reference.
Outcome · 15 Jan 2026, 11:17 pm
GVBL Reports Q3FY26 Results and Director Cessation Genomic Valley Biotech (GVBL) announced Q3FY26 results and a director change on 15-Jan'26. Q3 revenue was Rs. 5.00 Lakh, a 77.3% YoY decline and 44.4% QoQ decline. Net profit stood at Rs. 1.05 Lakh, down 93.2% YoY but up 218.4% QoQ. For 9MFY26, revenue fell 93.5% YoY to Rs. 23.00 Lakh, with net profit declining 91.1% YoY to Rs. 3.85 Lakh. Separately, Mr. Ashok Kumar ceased to be a Director effective 15-Jan'26 due to non-completion of KYC requirements.
Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/01/2026 ,inter alia, to consider and approve the unaudited financial ....
Intimation · 15 Jan 2026, 5:30 am
Genomic Valley Biotech (GVBL) to Announce Q3FY26 Results on Jan 15th Genomic Valley Biotech (GVBL) has scheduled a Board of Directors meeting on 15th Jan'26 to consider and approve the unaudited standalone financial results for the quarter and nine months ended 31st Dec'25. In compliance with SEBI insider trading regulations, the trading window for designated persons is closed from 01st Jan'26 until 48 hours after the results are publicly announced on 15th Jan'26.
Submission of voting results of 31st Annual General Meeting of the Company under Regulation 44(3) of the SEBI (listing Obligations & Disclosure Requirements) Regulations, 2015.
Annual General Meeting · 01 Jan 2026, 9:28 pm
Genomic Valley Biotech Shareholders Approve All Resolutions at 31st AGM Genomic Valley Biotech (GVBL) announced that all resolutions at its 31st Annual General Meeting on 31 Dec'25 were passed with 100% of votes in favour. Key approvals include the adoption of FY25 financial statements, re-appointment of director Ms. Parul Agrawal, and the appointment of Yogainder Kumar Gupta as an Independent Director. Additionally, shareholders approved the re-appointment of Mr. Yogesh Agrawal as Chairman & MD for five years and an alteration of the company's Memorandum of Association. Total valid votes cast were 1,407,959.
Please find enclosed herewith copy of proceeding of 31st Annual General Meeting of the company for your reference.
Annual General Meeting · 31 Dec 2025, 3:22 pm
Genomic Valley Biotech (GVBL) Outlines Resolutions at 31st Annual General Meeting Genomic Valley Biotech held its 31st AGM for FY25 on 31st Dec'25. Key resolutions included adopting the FY25 audited financial statements. Special business involved the re-appointment of Yogesh Agrawal as Chairman and MD for a five-year term effective 07th Sep'25, and approving an alteration to the company's Memorandum of Association (MOA) Object Clause. Other resolutions included director appointments, re-appointments, and the appointment of secretarial auditors for a five-year term. All resolutions were put to vote via remote e-voting and ballot.
Please find enclosed herewith the Notice of the Annual General Meeting for your reference.
Annual General Meeting · 09 Dec 2025, 9:22 pm
Genomic Valley Biotech to Hold 31st Annual General Meeting on 31st Dec'25 Genomic Valley Biotech Limited has scheduled its 31st Annual General Meeting (AGM) for 09:00 A.M. on 31st Dec'25 to consider its Annual Report for the financial year 2024-25. Key agenda items include the re-appointment of Ms. Parul Agrawal as a director and the re-appointment of Mr. Yogesh Agrawal as Chairman and Managing Director for a five-year term, effective 07th Sep'25, with a consolidated salary of Rs. 2,50,000 per month. Shareholders will also vote on appointing Mr. Yogainder Kumar Gupta as an Independent Director for a five-year term, appointing M/s. SBR & Co. LLP as Secretarial Auditors, and approving an alteration to the company's Memorandum of Association (MOA) to expand its business activities into areas like genomics, bioinformatics, and biotechnology research.
Compliance Under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Annual Report for The Financial Year 2024-25
Others (Uncategorized) · 09 Dec 2025, 9:12 pm
Genomic Valley Biotech Limited Submits FY 2024-25 Annual Report and Announces AGM Genomic Valley Biotech Limited has submitted its 31st Annual Report for the financial year ending 31st Mar'25. The company reported a significant increase in performance, with total revenue reaching Rs 84.84 lakh, up from Rs 16.66 lakh in the previous year. Profit After Tax surged to Rs 35.61 lakh compared to Rs 1.52 lakh in FY 2023-24, resulting in an EPS of Rs 1.17. The company is expanding its services in human genomics, leveraging Next-Generation Sequencing (NGS) and AI for diagnostics and research. The 31st Annual General Meeting (AGM) is scheduled to be held physically on 31st Dec'25 at 09:00 A.M. Key agenda items include the re-appointment of Chairman and Managing Director Mr. Yogesh Agrawal for a five-year term starting 07th Sep'25 with a remuneration of Rs 2,50,000 per month, and a proposal to alter the company's Memorandum of Association to broaden its business scope in biotechnology and genomics.